Free Word download β’ Edit online β’ Save & share with Drive β’ Export to PDF
A Patent License Agreement is a legally binding contract in which a patent owner (the licensor) grants a third party (the licensee) defined rights to make, use, sell, or import a patented invention β without transferring ownership of the underlying patent. The agreement specifies whether the grant is exclusive or non-exclusive, the territory and field of use in which the licensee may operate, the royalties or fees owed in exchange for those rights, and the obligations each party carries to maintain and enforce the patent. It functions as the legal foundation for commercializing any patented technology through a partner, manufacturer, or distributor rather than through direct operations.
Operating under a patent without a written license agreement exposes both parties to substantial risk. A licensee who manufactures or sells products based on a patented invention without a signed agreement is technically infringing β regardless of any oral understanding β and can face injunctions, damages, and disgorgement of profits. On the licensor's side, allowing use without a documented royalty structure creates an implied license that courts may interpret far more broadly than intended, potentially stripping the licensor of the ability to enforce the patent against others. An undocumented exclusive arrangement gives the licensee no enforceable exclusivity while leaving the licensor unable to demonstrate clean title to future investors or acquirers. A properly executed patent license agreement eliminates all of these exposures, establishes a clear royalty payment trail, and gives both parties enforceable rights if the commercial relationship breaks down. This template gives you a structured, lawyer-reviewable starting point that covers every material term β from royalty definitions to patent-challenge termination β so you can close the deal without starting from a blank page.
| If your situation is⦠| Use this template |
|---|---|
| Granting one licensee sole rights to the patent in a defined market | Exclusive Patent License Agreement |
| Granting multiple licensees rights to the same patent simultaneously | Non-Exclusive Patent License Agreement |
| Two parties exchanging rights to each other's patents | Patent Cross-License Agreement |
| Permanently transferring all patent rights to a buyer | Patent Assignment Agreement |
| Licensing both patents and related trade secrets or know-how together | Technology License Agreement |
| Licensing software covered by patents along with a source code grant | Software License Agreement |
| Permitting a licensee to grant sub-licenses to its own customers or partners | Sublicense Agreement |
Why it matters: A licensee can hold an exclusive patent license dormant indefinitely β blocking the licensor from commercializing with anyone else β while paying no royalties because sales never materialize.
Fix: Include an annual minimum royalty and a commercialization milestone schedule. Failure to meet either should automatically convert the exclusive license to non-exclusive or trigger a reversion right.
Why it matters: Licensees routinely take aggressive deductions for freight, taxes, bundled services, and intercompany transfers, collapsing the effective royalty base to a fraction of gross revenue.
Fix: Define 'Net Sales' with a closed list of permitted deductions β typically actual returns, volume discounts, and sales taxes β and cap total deductions at a defined percentage of gross sales.
Why it matters: A licensee can file an inter partes review at the USPTO while still paying royalties, using licensed cash flow to fund an attempt to invalidate the patent and eliminate the royalty obligation entirely.
Fix: Add a clause permitting the licensor to terminate immediately if the licensee, directly or through an affiliate, challenges the validity or enforceability of any licensed patent.
Why it matters: If the licensor stops paying maintenance fees and the patent lapses, the licensee loses all licensed rights with no contractual remedy β and potential competitors gain free access to the technology.
Fix: Give the licensee the right to pay maintenance fees directly and deduct those costs from future royalties if the licensor fails to do so within a defined cure period.
Why it matters: A sublicensee who has not accepted the confidentiality, field-of-use, or quality obligations of the original license can use the technology outside permitted boundaries β exposing the licensor with no direct contractual recourse.
Fix: Require that every sublicense agreement incorporates by reference, or restates in full, all material obligations of the original license, including field-of-use, territory, and confidentiality terms.
Why it matters: Without the right to inspect the licensee's sales records, the licensor has no practical way to verify that royalty reports are accurate β underpayment goes undetected indefinitely.
Fix: Include an annual audit right allowing the licensor, at its own cost, to engage an independent accountant to review the licensee's royalty calculations. Require the licensee to bear audit costs if underpayment exceeds 5%.
In plain language: Defines the core rights transferred β whether the license is exclusive or non-exclusive, the patent(s) covered, the licensed territory, and the permitted field of use.
Licensor hereby grants to Licensee a [exclusive / non-exclusive], non-transferable license under [PATENT NUMBER(S)] to make, have made, use, sell, and import the Licensed Products solely within the [TERRITORY] and solely within the [FIELD OF USE].
Common mistake: Omitting the field-of-use restriction when granting an exclusive license β without it, the licensee may claim rights across every industry the patent covers, blocking the licensor from other commercial opportunities.
In plain language: Sets the financial terms β upfront license fees, ongoing royalty rate, the royalty base (net sales, gross sales, or per-unit), milestone payments, and the payment schedule.
Licensee shall pay Licensor: (a) an upfront license fee of $[AMOUNT] due within [X] days of execution; (b) a running royalty of [X]% of Net Sales of Licensed Products; and (c) milestone payments as set out in Schedule A.
Common mistake: Failing to define 'Net Sales' precisely. Deductions for returns, freight, taxes, and discounts can reduce the royalty base dramatically β each permissible deduction must be listed explicitly.
In plain language: States whether the licensee may grant sublicenses to third parties, under what conditions, and whether sublicense revenues must be shared with the licensor.
Licensee may grant sublicenses under this Agreement only with the prior written consent of Licensor. Licensee shall pay Licensor [X]% of any sublicense fees and royalties received from sublicensees.
Common mistake: Granting unlimited sublicensing rights without a revenue-sharing obligation β allowing the licensee to profit substantially from sub-deals while the licensor receives only the original royalty rate.
In plain language: Allocates responsibility for paying patent maintenance fees, filing continuation applications, and prosecuting the patent before patent offices to keep it in force.
Licensor shall have the primary obligation to prosecute and maintain the Licensed Patents at its own cost. Licensee shall cooperate reasonably with Licensor in such prosecution and may, at its option, assume prosecution if Licensor elects to abandon any Licensed Patent.
Common mistake: Leaving prosecution responsibility unassigned. If the licensor stops paying maintenance fees and the patent lapses, the licensee loses all rights β with no contractual remedy.
In plain language: Each party warrants what they are representing to be true β the licensor typically warrants ownership and the right to grant the license; the licensee warrants authority to enter the agreement.
Licensor represents and warrants that: (a) it is the sole owner of the Licensed Patents; (b) it has full authority to grant the rights herein; and (c) to its knowledge, the Licensed Patents are valid and enforceable. LICENSOR MAKES NO WARRANTY THAT PRACTICE OF THE LICENSED PATENTS WILL NOT INFRINGE THIRD-PARTY RIGHTS.
Common mistake: Omitting the disclaimer of validity warranty. If the licensor warrants patent validity and the patent is later invalidated, the licensor faces a warranty-breach claim and potential royalty refund obligation.
In plain language: Establishes who has the right and obligation to sue third-party infringers, who bears the cost of litigation, and how any damages recovered are split.
Licensee shall promptly notify Licensor of any suspected infringement of the Licensed Patents. Licensor shall have the first right to bring suit. If Licensor elects not to proceed within [90] days of notice, Licensee may bring suit at its own expense, and any recovery shall be shared [X]% to Licensee and [X]% to Licensor.
Common mistake: Giving the exclusive licensee no right to enforce the patent independently. An exclusive licensee with no enforcement right cannot stop competitors from infringing β destroying the commercial value of the exclusivity.
In plain language: Allocates liability between the parties for third-party claims β typically the licensee indemnifies the licensor for product liability arising from the licensee's products, while the licensor indemnifies for IP ownership disputes.
Licensee shall indemnify, defend, and hold harmless Licensor from any third-party claims arising out of Licensee's manufacture, use, or sale of Licensed Products. Licensor shall indemnify Licensee against any third-party claims that the Licensed Patents are not owned by or licensed to Licensor.
Common mistake: Mutual indemnification with no carve-outs for gross negligence or willful misconduct β resulting in a party being obligated to indemnify claims arising from its own bad acts.
In plain language: Defines the duration of the license, conditions for early termination (breach, insolvency, non-performance), and the cure period before termination takes effect.
This Agreement commences on [DATE] and continues until the expiration of the last-to-expire Licensed Patent unless terminated earlier. Either party may terminate for material breach upon [30] days' written notice if the breach is not cured within that period. Licensor may terminate immediately upon Licensee's insolvency or challenge to the validity of the Licensed Patents.
Common mistake: No patent-challenge termination clause. Without it, a licensee can continue paying royalties at a reduced rate while simultaneously funding an inter partes review to invalidate the licensed patent.
In plain language: Requires the licensee to pay a minimum annual royalty or meet defined commercialization milestones, with failure triggering a license conversion or reversion to the licensor.
Licensee shall pay a minimum annual royalty of $[AMOUNT] regardless of actual Net Sales. Failure to meet the minimum in any calendar year shall convert this exclusive license to non-exclusive at Licensor's option, upon [60] days' written notice.
Common mistake: Exclusive licenses with no minimum royalty or commercialization obligation β allowing a licensee to warehouse the patent and prevent the licensor from working with anyone else indefinitely.
In plain language: Specifies which jurisdiction's law governs the contract and the mechanism for resolving disputes β litigation, arbitration, or mediation β including venue and choice of arbitral body.
This Agreement shall be governed by the laws of [STATE/COUNTRY]. Any dispute arising hereunder shall be resolved by binding arbitration administered by [AAA / ICC] in [CITY], except that either party may seek injunctive relief in any court of competent jurisdiction.
Common mistake: Selecting a governing law with no meaningful connection to either party. US courts apply the law of the state with the most significant relationship to the contract β a mismatch can result in an unexpected governing law being applied by a court.
Enter the licensor's and licensee's full legal entity names, registered addresses, and jurisdiction of incorporation. List every patent number, application number, and country of registration covered by the agreement in a Schedule.
π‘ Pull patent numbers from the patent office register on the day of signing to confirm current ownership status and that maintenance fees are paid up.
Choose exclusive, non-exclusive, or sole license. Specify the territory (e.g., worldwide, United States only, EU member states). Define the field of use narrowly enough to preserve the licensor's ability to license other markets.
π‘ If granting worldwide exclusivity in a broad field, add a reversion clause tied to minimum royalties β otherwise the licensor is locked out of all commercialization indefinitely.
Enter the upfront fee, running royalty percentage, and royalty base. Define 'Net Sales' with a complete list of permitted deductions. Set the royalty reporting period (quarterly is standard) and the due date for reports and payments.
π‘ Industry royalty benchmarks vary widely: pharmaceutical patents typically range from 2β10% of net sales; mechanical and electronics patents from 1β5%. Research comparable licenses before agreeing to a rate.
Decide whether the licensee may sublicense and whether it may have products manufactured by contract manufacturers ('have-made' rights). If sublicensing is permitted, set the revenue-sharing percentage and require that sublicense agreements flow down all material obligations.
π‘ Require the licensee to provide a copy of every sublicense agreement within 30 days of execution β this lets you verify that your IP obligations are being passed through correctly.
State which party is responsible for paying renewal fees and filing continuation applications. Include a step-in right allowing the licensee to take over prosecution if the licensor elects to abandon any covered patent.
π‘ For licenses covering pending applications, define what happens if the application does not issue β does the royalty obligation survive, reduce, or terminate?
For exclusive licenses, give the licensee a right to enforce the patent against infringers independently if the licensor does not act within a defined window (typically 90β180 days). Specify how litigation costs and recoveries are shared.
π‘ Licensees in regulated markets (pharma, medical devices) often need stand-alone enforcement rights to protect market exclusivity β do not leave this section as licensor-only.
Define the agreement's duration (typically life of the last patent). List termination triggers: uncured material breach, insolvency, patent challenge by licensee, or failure to meet minimum commercialization milestones. Specify what happens to existing inventory and sublicenses upon termination.
π‘ Include a sell-off period of 90β180 days post-termination for the licensee to deplete finished-goods inventory β without it, termination can leave the licensee with unmarketable stock.
Both parties must sign the agreement before the licensee manufactures, sells, or imports any product under the license. Backdating or executing after commercial activity has begun creates ambiguity about royalty accrual and may void representations made at signing.
π‘ Use a countersignature page that records execution date separately from the agreement date to avoid any question about when binding obligations arose.
A patent license agreement is a legally binding contract in which a patent holder grants another party permission to make, use, sell, or import a patented invention in exchange for royalties or other compensation. It transfers rights to practice the patent without transferring ownership of the patent itself. The agreement defines the scope, duration, territory, financial terms, and obligations of both parties.
An exclusive patent license grants rights only to the named licensee within the defined territory and field β even the licensor cannot practice the patent in that scope during the license term. A non-exclusive license allows the licensor to grant the same rights to multiple licensees simultaneously. Exclusive licenses command higher royalties and upfront fees but require stronger commercialization obligations to protect the licensor's interests.
Royalty rates vary significantly by industry and the strength of the patent. Pharmaceutical and biotech patents typically command 2β10% of net sales. Consumer electronics and mechanical patents commonly range from 1β5%. Software patents often generate 0.5β3%. The Georgia-Pacific factors β a 15-factor legal framework used by US courts β are the standard reference for determining a reasonable royalty in litigation and are a useful benchmark in negotiations.
Only if the patent license agreement explicitly permits it. Sublicensing rights are not implied β they must be granted in writing. When sublicensing is permitted, the original agreement should require the licensee to flow down all material obligations to the sublicensee and share a defined percentage of sublicense revenues with the licensor.
Under US law, a patent assignment generally does not automatically terminate an existing license β the new owner typically takes the patent subject to the license. However, this depends on whether the license was recorded with the USPTO and the specific terms of both the license and the assignment agreement. Including a clause requiring the licensor to bind any successor to the license terms is standard practice to avoid ambiguity.
A field-of-use restriction limits the licensee's rights to a specific application, industry, or market segment β for example, authorizing use of a chemical compound patent solely for agricultural applications. This allows the licensor to grant separate licenses for medical, industrial, or consumer applications to different parties, maximizing total royalty income. Without a field-of-use restriction, a broadly worded exclusive license can block the licensor from all commercial activity related to the patent.
For patent licenses involving significant royalty streams, exclusivity, or cross-border rights, legal review by a patent attorney or IP licensing specialist is strongly recommended. Patent law is highly technical, royalty structures have significant tax and valuation implications, and errors in the grant clause or royalty definition can cost far more to litigate than the cost of upfront legal advice. A template is a sound starting point; a lawyer tailors it to the specific patent, parties, and commercial structure.
A reversion clause returns licensed patent rights to the licensor if the licensee fails to meet defined performance obligations β such as minimum annual royalties, first commercial sale by a target date, or a regulatory approval milestone. Reversion clauses are especially important in exclusive licenses granted to startups or early-stage companies where commercialization risk is high. Without one, the licensor has no practical remedy if the licensee sits on the patent and does nothing with it.
Yes β under US law (MedImmune v. Genentech, 2007), a licensee generally retains the right to challenge patent validity even while paying royalties, without first breaching the license. In the EU, the position varies by member state. To manage this risk, licensors typically include a patent-challenge termination clause allowing immediate termination if the licensee initiates any invalidity proceeding, which creates a strong economic disincentive against filing a challenge.
A patent assignment permanently transfers full ownership of the patent from the inventor or owner to a buyer β the seller retains no ongoing rights or royalty interest. A patent license grants defined usage rights while the licensor retains ownership and continues to receive royalties. Use an assignment when the goal is a clean outright sale; use a license when the goal is ongoing income or retained ownership.
A technology license agreement typically covers a bundle of IP β patents, trade secrets, know-how, and sometimes copyrights β related to a defined technology. A patent license agreement covers registered patent rights only. When the commercial value of the technology depends on unpatented know-how or proprietary processes as much as on the patent itself, a broader technology license is more appropriate.
An NDA protects confidential information shared during patent licensing negotiations β it does not grant any rights to use or practice the patent. An NDA is typically executed before the patent license agreement to allow both parties to share sensitive technical and financial information during due diligence. The NDA and the license serve different, sequential purposes and are often both needed.
A software license agreement primarily governs copyright and contractual rights to use a software product β it does not specifically address patent grant clauses, royalty structures, or patent prosecution obligations. When a software product is covered by one or more patents and the licensor wants to grant explicit patent rights, a dedicated patent license or a combined software and patent license is needed to avoid implied-license ambiguity.
Milestone-heavy structures tied to FDA approval stages, reach-through royalties on research tool licenses, and compulsory licensing obligations under certain public health frameworks.
Cross-licensing portfolios across competitors, standard-essential patent (SEP) licensing under FRAND terms, and have-made rights for contract manufacturing in Asia.
Process patent licenses tied to production volume rather than sales value, geographic territory restrictions aligned to distribution channels, and quality control obligations embedded in the license.
Technology transfer office structures with equity-in-lieu-of-royalties provisions, sponsored research agreements running alongside the license, and Bayh-Dole Act compliance obligations for federally funded inventions.
US patent licenses are governed by federal patent law (35 U.S.C.) and the contract law of the chosen state. Recording the license with the USPTO protects the licensee against subsequent assignees. Under MedImmune v. Genentech (2007), licensees retain standing to challenge patent validity while paying royalties. The Georgia-Pacific framework (15 factors) governs reasonable royalty determination in infringement litigation and is widely used as a negotiation benchmark.
Canadian patent licenses are governed by the Patent Act (R.S.C. 1985, c. P-4) and applicable provincial contract law. Licenses need not be recorded with CIPO to be valid between the parties, but registration protects against third-party claims. Canada does not recognize the at-will patent challenge doctrine as broadly as the US β contractual patent-challenge termination clauses are generally enforceable. Bilingual agreement considerations may apply for Quebec-based licensees.
UK patent licenses are governed by the Patents Act 1977 and general contract law. Exclusive licensees have statutory standing to bring infringement proceedings in their own name under Section 67 of the Patents Act. Licenses should be registered at the UK Intellectual Property Office to be effective against third parties acquiring an interest in the patent. Post-Brexit, UK and EU patent rights are distinct β a license covering 'Europe' must be carefully drafted to specify whether it includes UK rights.
EU patent licensing is governed by national patent laws of each member state and the Technology Transfer Block Exemption Regulation (TTBER β Commission Regulation 316/2014), which sets safe harbors and restrictions for patent licenses between competitors and non-competitors. Field-of-use and territorial restrictions are generally permitted under TTBER within defined market-share thresholds. The Unified Patent Court (UPC), operational since 2023, provides a single forum for enforcing European patents across participating member states β licenses should specify whether UPC jurisdiction is opted in or out.
| Path | Best for | Cost | Time |
|---|---|---|---|
| Use the template | Straightforward domestic non-exclusive licenses with modest royalty values and no complex milestone structures | Free | 1β3 hours |
| Template + legal review | Exclusive licenses, cross-border grants, university spin-out deals, or any license with royalties exceeding $50,000 annually | $500β$2,500 for a patent attorney or IP licensing specialist review | 3β7 days |
| Custom drafted | Portfolio cross-licenses, SEP/FRAND licensing, pharma milestone deals, or any transaction involving equity in lieu of royalties | $3,000β$15,000+ | 2β6 weeks |
This document is one of 3,000+ business & legal templates included in Business in a Box.
Access over 3,000+ business and legal templates for any business task, project or initiative.
Customize your ready-made business document template and save it in the cloud.
Share your files and folders with your team. Create a space of seamless collaboration.
"Fantastic value! I'm not sure how I'd do without it. It's worth its weight in gold and paid back for itself many times."
"I have been using Business in a Box for years. It has been the most useful source of templates I have encountered. I recommend it to anyone."
"It has been a life saver so many times I have lost count. Business in a Box has saved me so much time and as you know, time is money."
Stop downloading documents. Start operating with clarity. Business in a Box gives you the Business Operating System used by over 250,000 companies worldwide to structure, run, and grow their business.
Start freeΒ Β·Β No credit card required
